<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653844</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0640</org_study_id>
    <nct_id>NCT04653844</nct_id>
  </id_info>
  <brief_title>RT-PCR Database Analysis for COVID-19 Infections and Re-infection</brief_title>
  <acronym>ReCOV</acronym>
  <official_title>SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire CERBA-MPL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CNRS (MIVEGEC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NÃ®mes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real&#xD;
      frequency of likely re-infection and subsequently the level of protection conferred by the&#xD;
      acquired immunity following primary-infection. We propose to analyze a large set of&#xD;
      laboratory data produced since the early beginning of the SARS-Cov2 spread in the French&#xD;
      population to identify recurrent infection events and, more generally, gain insight about&#xD;
      infection kinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 reinfection rate</measure>
    <time_frame>1 day</time_frame>
    <description>SARS-CoV-2 reinfection rate</description>
  </primary_outcome>
  <enrollment type="Actual">7000000</enrollment>
  <condition>Covid-19</condition>
  <condition>SARS-CoV Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        French population with a positive SARS-Cov2 diagnosis documented through a positive RT-PCR&#xD;
        result&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - People with at least one positive SARS-Cov2 RT-PCR result with a known sampling date&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Patient refusing to participate in research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Foulongne, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-Cov2 infection</keyword>
  <keyword>Positive SARS-Cov2 RT-PCR</keyword>
  <keyword>SARS-Cov2 immune status</keyword>
  <keyword>reinfection</keyword>
  <keyword>kinetics</keyword>
  <keyword>Rt-PCR</keyword>
  <keyword>immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

